The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency
Sonya Cressman(BC Cancer Agency), Stephen Lam(University of British Columbia), Emily McPherson(Mathematica Policy Research), Glenwood Goss(Ottawa Hospital), Natasha B. Leighl(Princess Margaret Cancer Centre), John C. English(University of British Columbia Hospital), Annette McWilliams, Kayvan Amjadi(Ottawa Hospital), William K. Evans(NHS Forth Valley), Christian Couture(Institut universitaire de cardiologie et de pneumologie de Québec), Serge Puksa(Juravinski Hospital), Don D. Sin(University of British Columbia), Paul Burrowes(University of Calgary), Kazuhiro Yasufuku(University Health Network), John R. Goffin(Juravinski Hospital), Alain Tremblay(Alberta Health Services), Simon Martel(Université du Québec), Harmanjatinder S. Sekhon(Ottawa Hospital), Daria Manos(Dalhousie University), John R. Mayo(Vancouver General Hospital), Ming‐Sound Tsao(Kumamoto University), Frances A. Shepherd(University Health Network), Heidi Schmidt(University Health Network), Stuart Peacock(BC Cancer Agency), Stefan J. Urbanski(University of Calgary), Martin C. Tammemägi(Brock University), Wan C. Tan(University of British Columbia), Garth Nicholas(Ottawa Regional Cancer Foundation), Reka Pataky(BC Cancer Agency), Geoffrey Liu(Princess Margaret Cancer Centre), Zhaolin Xu(Dalhousie University), David Hwang(University Health Network), Diana N. Ionescu(BC Cancer Agency), Michael R. Johnston(Purdue University West Lafayette), John Yee(BC Cancer Agency), Kam Soghrati(University Health Network), Paul MacEachern(University of Calgary), Sukhinder Atkar-Khattra(BC Cancer Agency)
Cited by 142
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k